About Zavante
Zavante is a company based in San Diego (United States) founded in 2015 was acquired by Nabriva in July 2018.. Zavante has raised $80.01 million across 5 funding rounds from investors including Nabriva, Frazier Healthcare Partners and Longitude Capital. Zavante offers products and services including ZOLYD and Clinical Trials Services. Zavante operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zavante Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zavante
Zavante offers a comprehensive portfolio of products and services, including ZOLYD and Clinical Trials Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational injectable for treating multi-drug resistant bacterial infections
Conducts trials for new antibiotics targeting serious hospital infections
Funding Insights of Zavante
Zavante has successfully raised a total of $80.01M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $10.0M
-
First Round
First Round
(05 May 2015)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Debt – Conventional - Zavante | Valuation |
investors |
|
| Mar, 2016 | Amount | Series A - Zavante | Valuation |
investors |
|
| Mar, 2016 | Amount | Series A - Zavante | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zavante
Zavante has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Nabriva, Frazier Healthcare Partners and Longitude Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zavante
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Zavante
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zavante Comparisons
Competitors of Zavante
Zavante operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zavante
Frequently Asked Questions about Zavante
When was Zavante founded?
Zavante was founded in 2015.
Where is Zavante located?
Zavante is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Zavante a funded company?
Zavante is a funded company, having raised a total of $80.01M across 5 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on May 05, 2015.
What does Zavante do?
Zavante is a US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. Its lead product candidate, ZTI-01, ZOLYD, is a first-in-class injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. ZTI-01ZOLYD, or IV Fosfomycin, is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enol-pyruvyl transferase, also known as MurA. As on Aug.2017, ZOLYD is in Phase III trials for the treatment of cUTI, including acute pyelonephritis. The other indications for cUTI are cIAI, ABSSSI, HABPVABP, and others.
Who are the top competitors of Zavante?
Zavante's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does Zavante offer?
Zavante offers ZOLYD and Clinical Trials Services.
Who are Zavante's investors?
Zavante has 4 investors. Key investors include Nabriva, Frazier Healthcare Partners, Longitude Capital, and Aisling Capital.